Cancer Immunology Reserch

Cancer Immunol Res. 2025 Mar 25. doi: 10.1158/2326-6066.CIR-24-0743. Online ahead of print. ABSTRACT Microvascular proliferation (MVP) is a disease-defining hallmark of glioblastoma (GBM) and other World Health Organization (WHO) grade 4 gliomas. MVP also serves as a poor prognostic marker in various solid tumors. Despite its clinical significance, the mechanisms and biological consequences of MVP … Read more

Cancer Immunol Res. 2025 Mar 14:OF1-OF2. doi: 10.1158/2326-6066.CIR-25-0202. Online ahead of print. ABSTRACT Biomarkers of responsiveness to immune checkpoint blockade (ICB) are heavily sought given the breadth and depth of the use of ICB in cancer. PD-L1 expression was among the first biomarkers identified, but multiple factors have precluded more widespread use. In this issue, … Read more

Cancer Immunol Res. 2025 Mar 14:OF1-OF20. doi: 10.1158/2326-6066.CIR-24-0151. Online ahead of print. ABSTRACT Immunotherapies have had unprecedented success in the treatment of multiple cancer types, albeit with variable response rates. Unraveling the complex network of immune cells within the tumor microenvironment (TME) may provide additional insights to enhance antitumor immunity and improve clinical response. Many … Read more

Cancer Immunol Res. 2025 Mar 12. doi: 10.1158/2326-6066.CIR-24-0758. Online ahead of print. ABSTRACT Agonistic anti-CD40 with anti-PD-1 can elicit objective responses in a small number of patients with pancreatic ductal adenocarcinoma (PDA). Better understanding of their individual effects on the PDA tumor microenvironment will help inform new strategies to further improve outcomes. Herein, we map … Read more

Cancer Immunol Res. 2025 Mar 11. doi: 10.1158/2326-6066.CIR-24-0379. Online ahead of print. ABSTRACT Immune checkpoint blockade (ICB) has revolutionized the therapeutic landscape across various cancer types. However, the emergence of resistance to ICB therapy limits its clinical application. Therefore, it is necessary to better understand immune-resistance mechanisms that could be targeted by actionable drugs, and … Read more

Cancer Immunol Res. 2025 Mar 11. doi: 10.1158/2326-6066.CIR-24-0804. Online ahead of print. ABSTRACT mRNA vaccines are recognized as potent tools for immunization against viral diseases and cancer. However, the lack of a vaccine adjuvant limits the efficacy of these treatments. Here, we used cGAS mRNA, which encodes the DNA innate immune sensor, complexed with lipid … Read more

Cancer Immunol Res. 2025 Mar 11. doi: 10.1158/2326-6066.CIR-24-0263. Online ahead of print. ABSTRACT Cytotoxic chemotherapy that kills cancer cells can also elicit anti-tumor immune responses. Therefore, understanding the immunogenic context of cytotoxic chemotherapy can improve combination immunotherapies. In this study, we sought to improve our understanding about dendritic cell (DC) dynamics in cytotoxic chemotherapy-treated tumor … Read more

Cancer Immunol Res. 2025 Mar 4;13(3):309. doi: 10.1158/2326-6066.CIR-13-3-WWR. NO ABSTRACT PMID:40033981 | DOI:10.1158/2326-6066.CIR-13-3-WWR

Cancer Immunol Res. 2025 Feb 26. doi: 10.1158/2326-6066.CIR-24-1094. Online ahead of print. ABSTRACT Denosumab, a RANKL inhibitor, is primarily used to prevent osteoclastogenesis in the treatment of conditions such as osteoporosis, bone metastasis, and giant cell tumour of bone (GCTB). RANKL also plays an important role in immunity by activating NF-κB and its target genes, … Read more

Cancer Immunol Res. 2025 Feb 25:OF1-OF7. doi: 10.1158/2326-6066.CIR-24-1046. Online ahead of print. ABSTRACT The advent of syngeneic mouse tumor models provided the scientific foundation for cancer immunotherapies now in widespread use. However, in many respects, these models do not faithfully recapitulate the interactions between cancer cells and the immune systems of human patients who have … Read more